Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion
Galasso M1, Feld JJ2, Watanabe Y1, Pipkin M1, Summers C1, Ali A1, Qaqish R1, Chen M1, Ribeiro RVP1, Ramadan K1, Pires L1, Bagnato VS3, Kurachi C3, Cherepanov V4, Moonen G1, Gazzalle A1, Waddell TK1, Liu M1, Keshavjee S1, Wilson BC5, Humar A6, Cypel M7,8. (Multi-Organ Transplant Program, University Health Network, Toronto, M5G 2C4, ON, Canada). firstname.lastname@example.org.
Nat Commun. 2019 Jan 29;10(1):481. doi: 10.1038/s41467-018-08261-z.
Availability of organs is a limiting factor for lung transplantation, leading to substantial mortality rates on the wait list. Use of organs from donors with transmissible viral infections, such as hepatitis C virus (HCV), would increase organ donation, but these organs are generally not offered for transplantation due to a high risk of transmission. Here, we develop a method for treatment of HCV-infected human donor lungs that prevents HCV transmission. Physical viral clearance in combination with germicidal light-based therapies during normothermic ex-vivo Lung Perfusion (EVLP), a method for assessment and treatment of injured donor lungs, inactivates HCV virus in a short period of time. Such treatment is shown to be safe using a large animal EVLP-to-lung transplantation model. This strategy of treating viral infection in a donor organ during preservation could significantly increase the availability of organs for transplantation and encourages further clinical development.
PMID: 30696822. PMCID: PMC6351537. DOI: 10.1038/s41467-018-08261-z
Full text at: https://www.nature.com/articles/s41467-018-08261-z